All In Biotech

NDA 021067 · Organon LLC

Asmanex Twisthaler

Mometasone Furoate · Inhalation

Last checked: Nov 20, 2026Latest source record: Feb 16, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2005

Mar 30, 2005

Approved uses

2

Original approval plus efficacy supplements

Registered trials

251

94 Phase 3, 12 recruiting

FAERS reports

18,509

9,021 serious, 620 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 7, 2026.

ASMANEX ® TWISTHALER ® is indicated for the maintenance treatment of asthma as prophylactic therapy in adult and pediatric patients 4 years of age and older. Limitations of Use ASMANEX TWISTHALER is not indicated for the relief of acute bronchospasm. ASMANEX TWISTHALER is not indicated in children less than 4 years of age. ASMANEX TWISTHALER is a corticosteroid indicated for maintenance treatment of asthma as prophylactic therapy in patients 4 years of age and older. ( 1 ) Limitations of Use: ASMANEX TWISTHALER is not indicated for the relief of acute bronchospasm ( 1 , 5.2 ) or in children less than 4 years of age ( 1 , 8.4 ).

Mechanism: Mometasone furoate is a corticosteroid demonstrating potent anti-inflammatory activity. The precise mechanism of corticosteroid action on asthma is not known. Inflammation is an important component in the pathogenesis of asthma. Corticosteroids have been shown to have a wide range of inhibitory effects on multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, and lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, and cytokines) involved in inflammation and in the asthmatic response. These anti-inflammatory actions of corticosteroids may contribute...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • ASMANEX TWISTHALER · MOMETASONE FUROATE 0.11MG/INH · POWDER, INHALATION · Prescription
  • ASMANEX TWISTHALER · MOMETASONE FUROATE 0.22MG/INH · POWDER, INHALATION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Mometasone Furoate" as an intervention, any sponsor and status, largest first.

All 251 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • no adverse event3,494
  • product quality issue2,952
  • poor quality device used2,546
  • device malfunction1,824
  • dyspnoea1,727
  • drug dose omission1,496
  • asthma1,297
  • drug ineffective1,275
  • cough1,233
  • headache1,147
  • product dose omission issue939
  • fatigue905

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200457
200557
200665
200795
2008152
2009127
2010150
2011153
2012235
2013268
2014629
20151,030
20161,110
20171,079
20181,673
20191,719
20201,386
20211,559
20221,792
20231,327
20241,137
20251,129
20261,580

Recalls

3 FDA enforcement reports for this application.

  • May 28, 2024 · Class III · Ongoing

    Defective Container

  • May 28, 2024 · Class III · Ongoing

    Defective Container

  • Jan 26, 2022 · Class II · Terminated

    CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 420 on PubMed

Sponsor: Organon LLC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.